Cirrhosis future or investigational therapies: Difference between revisions
| Line 13: | Line 13: | ||
*[[Entecavir]] in [[decompensated]] Hepatitis B Viral cirrhosis.<ref name="pmid20006400">{{cite journal| author=Fontana RJ| title=Entecavir in decompensated HBV cirrhosis: the future is looking brighter. | journal=J Hepatol | year= 2010 | volume= 52 | issue= 2 | pages= 147-9 | pmid=20006400 | doi=10.1016/j.jhep.2009.10.025 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20006400 }} </ref> | *[[Entecavir]] in [[decompensated]] Hepatitis B Viral cirrhosis.<ref name="pmid20006400">{{cite journal| author=Fontana RJ| title=Entecavir in decompensated HBV cirrhosis: the future is looking brighter. | journal=J Hepatol | year= 2010 | volume= 52 | issue= 2 | pages= 147-9 | pmid=20006400 | doi=10.1016/j.jhep.2009.10.025 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20006400 }} </ref> | ||
== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 15:09, 7 September 2012
|
Cirrhosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case studies |
|
Cirrhosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Cirrhosis future or investigational therapies |
|
Risk calculators and risk factors for Cirrhosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]
Overview
Cirrhosis is a complication of liver disease, which result in irreversible scarring, and loss of hepatocytes. Although cirrhosis has many etiologies, but alcohol and viral Hepatitis B and C are the main causes.
Research is going on to determine the mechanism of scar formation and how to interrupt or reverse this process.[1] Newer therapies are being developed against viral causes of liver diseases. Like Hepatitis B vaccine, vaccines are currently under development for Hepatitis C.
Future or Investigational Therapies
The following therapies are under trial:
- Obeticholic acid (OCA) for patients with primary biliary cirrhosis.[2]
- Boehringer Ingelheim’s investigational direct-acting antiviral compounds: BI 201335 (protease inhibitor) plus BI 207127 (polymerase inhibitor) for the treatment of Hepatitis C induced Cirrhosis.[3]
- Entecavir in decompensated Hepatitis B Viral cirrhosis.[4]
References
- ↑ Iredale JP (2003). "Cirrhosis: new research provides a basis for rational and targeted treatments". BMJ. 327 (7407): 143–7. doi:10.1136/bmj.327.7407.143. PMC 1126509. PMID 12869458.
- ↑ Lindor KD (2011). "Farnesoid X receptor agonists for primary biliary cirrhosis". Curr Opin Gastroenterol. 27 (3): 285–8. doi:10.1097/MOG.0b013e32834452c8. PMID 21297469.
- ↑ Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B; et al. (2011). "Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection". Gastroenterology. 141 (6): 2047–55, quiz e14. doi:10.1053/j.gastro.2011.08.051. PMID 21925126.
- ↑ Fontana RJ (2010). "Entecavir in decompensated HBV cirrhosis: the future is looking brighter". J Hepatol. 52 (2): 147–9. doi:10.1016/j.jhep.2009.10.025. PMID 20006400.